Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 226, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113842
Keywords
Glaucoma; Drug treatment; High intraocular pressure; OHT
Categories
Funding
- National Natural Science Foundation of China [81900339]
- High-level Talents Scientific Research Initiation Project of Chengdu Sport University [D400802]
- Key Research and Development Projects in Chengdu [2020-YF05-00058-SN]
- Key Research and Development Projects in Sichuan Province [2020YFS0399]
- Sichuan Provincial Administration of Traditional Chinese Medicine [2018HJZX013]
- Department of Science and Technology of Sichuan Province [2018JY0542]
- Health and Family Planning Commission of Sichuan Province [18PJ025]
- National Key Research and Development Program of China [2020YFC2005500]
- Key Research and Development Program of Science and Technology Department of Sichuan Province [2019YFS0514]
- Clinical Research and Transformation Fund of Sichuan Provincial People's Hospital [2021LZ03, JDZX2015210, 2018GZ2011005]
Ask authors/readers for more resources
Glaucoma is the third leading cause of blindness worldwide, with the number of patients projected to increase. High intraocular pressure is a major risk factor and cause of glaucoma, and drug therapy to lower intraocular pressure remains the first-line treatment.
Glaucoma is the third leading cause of blindness and impairment of vision worldwide, after refractive errors and cataracts. According to the survey, the number of people with glaucoma is more than 76 million, with projections increasing to 112 million by 2040. With the coming of an aging society, the number of people suffering from glaucoma will increase day by day. Glaucoma is a heterogeneous disease characterized by damage to the head of the optic nerve and visual field. High intraocular pressure is a major risk and cause of glaucoma optic neuropathy. Therefore, drug lowering intraocular pressure therapy is still the first-line therapy in clinical practice. Here, the targets, structure-activity relationship, and clinical progress of drugs for the treatment of glaucoma are reviewed. (C) 2021 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available